NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 450 participants.

Also called NCT04205578

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose diagnostic
Phase
Phase 3
Enrolled
  • 450 participants (planned count) (from the registry)
Sponsor
yuanli Zhao (from the registry)
Registry
  • NCT NCT04205578
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04205578. Randomized; single masking; primary purpose diagnostic. Start 2020-01 (anticipated); primary completion 2022-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events
Acronym
NICE-MMD
Condition
Moyamoya Disease
Condition
Ischemic Cerebral Infarction
Condition
Ischemic Cerebrovascular Accident
Intervention (Drug)
dl-3-n-butylphthalide (NBP)
Intervention (Drug)
Normal Saline 0.9% Infusion Solution
Lead sponsor
yuanli Zhao (class: other)
Collaborator
Peking University International Hospital (class: other)

Record details

Record id
cardio:ct-nct04205578
Content hash
7fb0c2800ad3be7e309b1fed9d77871530ec6c33401bcc138e1be5284bf24dee